DavidOMalleyMD

PubMed

• Correction: Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus.
  Uksha Saini, Brentley Q Smith, Kalpana Deepa Priya Dorayappan, Ji Young Yoo, G Larry Maxwell, Balveen Kaur, Ikuo Konishi, David O'Malley, David E Cohn, Karuppaiyah Sel...> ;Journal of Ovarian Research. 2023 Feb 13
• 1 citations
  Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus.
  Uksha Saini, Brentley Q Smith, Kalpana Deepa Priya Dorayappan, Ji Young Yoo, G Larry Maxwell, Balveen Kaur, Ikuo Konishi, David O'Malley, David E Cohn, Karuppaiyah Sel...> ;Journal of Ovarian Research. 2022 Dec 7
• 4 citations
  A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
  John H Farley, William E Brady, David O'Malley, Keiichi Fujiwara, Kan Yonemori, Albert Bonebrake, Angeles Alvarez Secord, Jean-Marie Stephan, Joan L Walker, Joo-Hyun N...> ;Gynecologic Oncology. 2022 Dec 1
• 4 citations
  The contemporary presentation and diagnosis of endometrial cancer recurrence: When, where, and how?
  Courtney J Riedinger, Jenna M Patterson, Floor J Backes, David O'Malley, Kristin L Bixel, Larry J Copeland, David E Cohn, Paul J Goodfellow, Casey M Cosgrove> ;Gynecologic Oncology. 2022 Nov 1
• 2 citations
  High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune c...
  Corinne A Calo, David A Barrington, Morgan Brown, Lynette Gonzalez, Jae Baek, Allison Huffman, Jason Benedict, Floor Backes, Laura Chambers, David Cohn, Larry Copeland...> ;Gynecologic Oncology Reports. 2022 Aug 1
• Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer.
  Dubay RA, Rose PG, O'Malley DM, Shalodi AD, Ludin A, Selim MA> ;Gynecologic oncology.
• 111 citations
  Minimal uterine serous carcinoma: a clinicopathological study of 40 cases.
  Pei Hui, David M. O'Malley, Fattaneh A. Tavassoli, Peter E. Schwartz> ;Modern Pathology. 2005 Jan 1
• Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol.
  Sapi E, Alvero AB, Chen W, O'Malley D, Hao XY, Dwipoyono B, Garg M, Kamsteeg M, Rutherford T, Mor G> ;Oncology research.
• Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
  Kelly MG, O'malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE> ;Gynecologic oncology.
• 64 citations
  Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells.
  David O'Malley, David Brown, Graham Edmund Kelly, Manish Garg, Wei Chen, Thomas J. Rutherford, Gil Mor> ;Cancer. 2006 Feb 1
• Ovarian cancer. Clinical practice guidelines in oncology.
  Morgan RJ, Alvarez RD, Armstrong DK, Boston B, Chen LM, Copeland L, Fowler J, Gaffney DK, Gershenson D, Greer BE, Grigsby PW, Havrilesky LJ, Johnston C, Lancaster JM, ...> ;Journal of the National Comprehensive Cancer Network : JNCCN.
• Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer.
  Bakkum-Gamez JN, Richardson DL, Seamon LG, Aletti GD, Powless CA, Keeney GL, O'Malley DM, Cliby WA> ;Obstetrics and gynecology.
• Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.
  Fader AN, Drake RD, O'Malley DM, Gibbons HE, Huh WK, Havrilesky LJ, Gehrig PA, Tuller E, Axtell AE, Zanotti KM, Uterine Papillary Serous Carcinoma (UPSC) Consortium> ;Cancer.
• 64 citations
  Use of negative pressure therapy on closed surgical incisions: a case series.
  James P. Stannard, Broadus Zane Atkins, David O'Malley, Hardayal Singh, Brent Bernstein, Michael Fahey, Derek L. Masden, Christopher E. Attinger> ;Wounds. 2009 Aug 1
• 66 citations
  Use of negative pressure therapy on closed surgical incisions: a case series.
  James P. Stannard, Broadus Zane Atkins, David O'Malley, Hardayal Singh, Brent Bernstein, Michael Fahey, Derek L. Masden, Christopher E. Attinger> ;Ostomy/wound Management. 2009 Aug 1
• Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer.
  Seamon LG, Carlson MJ, Richardson DL, Cohn DE, Fowler JM, Copeland LJ, O'Malley DM> ;International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
• Epithelial ovarian cancer.
  Morgan RJ, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele...> ;Journal of the National Comprehensive Cancer Network : JNCCN.
• 29 citations
  Phase II Evaluation of Phenoxodiol in Combination With Cisplatin or Paclitaxel in Women With Platinum/Taxane-Refractory/Resistant Epithelial Ovarian, Fallopian Tube, o...
  Michael G. Kelly, Gil Mor, David M. O'Malley, Lisa Baker, Masoud Azodi, Peter E. Schwartz, Thomas J. Rutherford> ;International Journal of Gynecological Cancer. 2011 Apr 1
• Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?
  Bakkum-Gamez JN, Richardson DL, Seamon LG, Aletti GD, Powless CA, Keeney GL, O'Malley DM, Cliby WA> ;International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
• 1 citations
  An introduction to research for primary dental care clinicians part 9: stage 10. Writing up and disseminating the results.
  Kenneth A Eaton, Laura Wiles, David O'Malley> ;Primary Dental Care. 2012 Apr 1
• The Ohio Patient Navigation Research Program: does the American Cancer Society patient navigation model improve time to resolution in patients with abnormal screening ...
  Paskett ED, Katz ML, Post DM, Pennell ML, Young GS, Seiber EE, Harrop JP, DeGraffinreid CR, Tatum CM, Dean JA, Murray DM, Ohio Patient Navigation Research Program> ;Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
• Here it comes....the role of cost-effective analysis.
  Salani R, O'Malley DM> ;Gynecologic oncology.
• Ovarian cancer, version 3.2012.
  Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin ...> ;Journal of the National Comprehensive Cancer Network : JNCCN.
• Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
  Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O'Malley DM> ;International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
• Ovarian cancer, version 2.2013.
  Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulon...> ;Journal of the National Comprehensive Cancer Network : JNCCN.
• Join now to see all